Altimmune, Inc. Common Stock
Symbol: ALT (NASDAQ)
3.92
▼ (-0.38%) -0.015
Company Description:
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.
Key Stats
- Today's Open: $3.94
- Today's High: $4.054
- Today's Low: $3.881
- Today's Volume: 2.56M
- Yesterday Close: $3.93
- Yesterday High: $3.95
- Yesterday Low: $3.83
- Yesterday Volume: 2.10M
- Last Min Volume: 7
- Last Min High: $3.915
- Last Min Low: $3.915
- Last Min VWAP: $3.915
Company Profile
- Name: Altimmune, Inc. Common Stock
- Website: https://www.altimmune.com
- Listed Date: 2005-10-06
- Location: GAITHERSBURG, MD
- Market Status: Active
- CIK Number: 0001326190
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $346.85M
- Round Lot: 100
- Outstanding Shares: 88.26M
- Asset Type: CS
RECENT FILINGS FOR ALT
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-03 | 4 | View |
| 2025-10-03 | 4 | View |
| 2025-10-03 | 3 | View |
| 2025-10-03 | 8-K | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-29 | 4 | View |
| 2025-09-25 | 8-K | View |
| 2025-09-17 | 4 | View |
| 2025-09-17 | 3 | View |
| 2025-08-19 | UPLOAD | View |
| 2025-08-15 | ARS | View |
| 2025-08-15 | DEF 14A | View |
| 2025-08-12 | CORRESP | View |
Latest News on ALT